| Product Unit Size | Cost | Quantity | Stock |
|---|
SU-9516 is an inhibitor of cyclin-dependent kinase (CDK), with selectivity for CDK2. It induces apoptosis in colon carcinoma cells. In leukemic cells, it downregulates Mcl-1, an antiapoptotic protein, leading to mitochondrial injury and cell death.
| Cas No. | 377090-84-1 |
|---|---|
| Purity | ≥98% |
| Formula | C13H11N3O2 |
| Formula Wt. | 241.25 |
| IUPAC Name | (3Z)-3-(1H-Imidazol-4-ylmethylene)-5-methoxy-1,3-dihydro-2H-indol-2-one |
| Synonym | SU9516 |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Opyrchal M., Salisbury J., et al. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 45(3):1193-9 (2014). PMID:24970653.
Lane M., Yu B., et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61(16):6170-7 (2001). PMID: 11507069.
Gao N., Kramer L., et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 70(2):645-55 (2006). PMID: 16672643.